CathVision

CathVision

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CathVision is a Copenhagen-based private company, founded in 2010, that is commercializing the ECGenius™ System, an FDA-cleared EP recording platform designed to acquire high-fidelity cardiac electrical signals. The company is augmenting this hardware with its CARDIALYTICS™ suite of AI-based analytic tools for automated, real-time analysis during procedures like atrial fibrillation ablation. By addressing the limitations of traditional, noisy EP recording systems, CathVision aims to become a new standard in the EP lab, integrating advanced signal acquisition with decision-support software.

Cardiovascular

Technology Platform

Integrated hardware-software platform combining the ECGenius™ high-fidelity electrophysiology recording system with the CARDIALYTICS™ suite of AI-based analytic tools for real-time procedural decision support.

Opportunities

The large and growing market for atrial fibrillation treatment, coupled with widespread dissatisfaction with legacy EP recording systems, creates a significant entry point for a superior technology.
The integration of AI-based analytics offers a path to higher-margin, recurring software revenue and can establish a defensible ecosystem that improves clinical workflow and outcomes.

Risk Factors

The company faces formidable competition from entrenched incumbents with integrated EP lab systems.
Successful commercialization requires proving clear clinical utility to drive adoption in a cost-conscious hospital environment.
Furthermore, the development and regulatory approval of its AI software suite carries significant technical and regulatory uncertainty.

Competitive Landscape

CathVision competes directly with large, established medical device companies like Abbott, Boston Scientific, and Johnson & Johnson (Biosense Webster), which offer integrated EP recording and mapping systems as part of broader capital equipment and disposable catheter portfolios. Its differentiation is a singular focus on superior core signal acquisition and AI-driven analytics, rather than being one component of a larger capital stack.